<code id='E4F21FAE0F'></code><style id='E4F21FAE0F'></style>
    • <acronym id='E4F21FAE0F'></acronym>
      <center id='E4F21FAE0F'><center id='E4F21FAE0F'><tfoot id='E4F21FAE0F'></tfoot></center><abbr id='E4F21FAE0F'><dir id='E4F21FAE0F'><tfoot id='E4F21FAE0F'></tfoot><noframes id='E4F21FAE0F'>

    • <optgroup id='E4F21FAE0F'><strike id='E4F21FAE0F'><sup id='E4F21FAE0F'></sup></strike><code id='E4F21FAE0F'></code></optgroup>
        1. <b id='E4F21FAE0F'><label id='E4F21FAE0F'><select id='E4F21FAE0F'><dt id='E4F21FAE0F'><span id='E4F21FAE0F'></span></dt></select></label></b><u id='E4F21FAE0F'></u>
          <i id='E4F21FAE0F'><strike id='E4F21FAE0F'><tt id='E4F21FAE0F'><pre id='E4F21FAE0F'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          entertainment

          author:Wikipedia    - browse:72
          Dozens of sickle cells in a whirlpool — coverage from STAT
          Adobe

          Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes. 

          The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?

          advertisement

          “We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore